BuzzSparks.org

bluebird bio


Genetix Pharmaceuticals Renamed bluebird bio Genetix is a specializes in gene therapy, looking to develop breakthrough treatments for severe genetic disorders. The company’s platform treats the cause of genetic diseases by placing a healthy gene...

Founded in 1992
Homepage:
Total money raised: $134.3M

02139 840 Memorial Drive

Cambridge
Cambridge
USA MA

Phone: (617) 491 5601

Updated on Aug 17, 2013
bluebird bio at CrunchBase
Nick Leschly CEO
Mitchell H. Finer Chief Scientific Officer
Linda C. Bain Vice President, Finance and Business Operations
John Maraganore Board of Directors
Richard E. T. Smith Vice President, Investor Relations
Daniel Lynch Board of Directors
Steven Gillis Board of Directors
Dr. Axel Polack Board of Directors
Jeffrey T. Walsh Chief Operating Officer
Cyrus Mozayeni Senior Director, Business Development
Wendy L. Dixon Board of Directors
Geert Jan Mulder Board of Directors
Robert I. Tepper Board of Directors
Past
Walter C. Ogier President and CEO
Philip Reilly Chief Medical Officer

June, 2013

bluebird bio IPO
Stock symbol: NASDAQ:BLUE

October, 2012

bluebird bio raised $9.3M in unattributed round from California Institute for Regenerative Medicine

bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy Clinical Development    in.finance.yahoo.com

July, 2012

bluebird bio raised $60M in a Series D round from Deerfield Partners, RA Capital Management, ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners, and Ramius Advisors

bluebird bio Secures $60 Million in Oversubscribed Financing    in.finance.yahoo.com

April, 2011

bluebird bio raised $30M in unattributed round from ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners, and Easton Capital

bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team    live-pr.com

March, 2011

appointed its first scientific advisory board (SAB) members today

Bluebird bio names first SAB members, expanding clinical trials    masshightech.com

Bluebird bio forms potential $4.2M deal with French Muscular Dystrophy Association    masshightech.com

December, 2010

collaborating with French firm Généthon in finding manufacturing solutions for gene therapy products and lentiviral vectors

Bluebird bio, French firm team in gene therapy manufacturing    masshightech.com

September, 2010

Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer    tmcnet.com

March, 2010

bluebird bio raised $35M in a Series B round from Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion Capital Partners, and Easton Capital

Genetix raises $35M to advance gene therapies    fiercebiotech.com

1992

bluebird bio was founded in 1992